Kolltan Pharmaceuticals Receives $5,000,000 Series A Round

  • Feed Type
  • Date
    8/18/2009
  • Company Name
    Kolltan Pharmaceuticals
  • Mailing Address
    300 George St New Haven, CT 06511
  • Company Description
    Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need.
  • Website
    http://www.kolltan.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    HBM Bioventures
  • Venture Investor
    Undisclosed